{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:05:34Z","timestamp":1793160334016,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.jhep.2005.11.027","type":"journal-article","created":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T07:42:00Z","timestamp":1133250120000},"page":"S132-S139","source":"Crossref","is-referenced-by-count":191,"special_numbering":"S1","title":["Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management"],"prefix":"10.1016","volume":"44","author":[{"given":"Marina","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2005.11.027_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with HIV infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2004.11.017","article-title":"Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era","volume":"42","author":"Kramer","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.11.027_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0168-8278(01)00291-4","article-title":"Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases","volume":"36","author":"Clark","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.11.027_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/00126334-200204010-00009","article-title":"Trends in diseases reported on US death certificates that mentioned HIV infection, 1987\u20131999","volume":"29","author":"Selik","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2005.11.027_bib5","unstructured":"CDC. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997\u20132000. Morb Mortal Wkly Rep; 2001;49:1153\u20136."},{"key":"10.1016\/j.jhep.2005.11.027_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(00)04139-8","article-title":"Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1","volume":"357","author":"Benn","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.027_bib7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(99)80008-7","article-title":"Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial","volume":"354","author":"Guay","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.027_bib8","article-title":"Table of grading severity of adult adverse experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectiosus Disease,","author":"AIDS Clinical Trials Group","year":"1996","journal-title":"Bethesda;"},{"key":"10.1016\/j.jhep.2005.11.027_bib9","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1073\/pnas.231140698","article-title":"Mechanism of indinavir-induced hyperbilirubinemia","volume":"98","author":"Zucker","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2005.11.027_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jhep.2005.11.027_bib11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/00002030-199810000-00025","article-title":"Hepatotoxicity after introduction of highly active antiretroviral therapy","volume":"12","author":"Rodr\u00edguez-Rosado","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib12","doi-asserted-by":"crossref","first-page":"F115","DOI":"10.1097\/00002030-199912030-00002","article-title":"Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996\u20131998","volume":"13","author":"Saves","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib13","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1097\/00002030-200012220-00011","article-title":"Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection","volume":"14","author":"Den Brinker","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib14","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1128\/AAC.44.12.3451-3455.2000","article-title":"Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients","volume":"44","author":"Saves","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.11.027_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00126334-200108150-00002","article-title":"Risk factors for severe hepatic injury following the introduction of HAART","volume":"27","author":"N\u00fa\u00f1ez","year":"2001","journal-title":"J Acquir Immune Def Syndr"},{"key":"10.1016\/j.jhep.2005.11.027_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00126334-200107010-00017","article-title":"Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy","volume":"27","author":"Bonfanti","year":"2001","journal-title":"J Acquir Immune Def Syndr"},{"key":"10.1016\/j.jhep.2005.11.027_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00042560-200110010-00002","article-title":"Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART","volume":"28","author":"D'Arminio Monforte","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2005.11.027_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00042560-200201010-00005","article-title":"Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection","volume":"29","author":"Aceti","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2005.11.027_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","article-title":"Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy","volume":"186","author":"Wit","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00042560-200205010-00008","article-title":"Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy","volume":"30","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2005.11.027_bib21","unstructured":"Maida I, Babudieri S, Selva C, et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior and after initiation of HAART: role of HCV genotypes. AIDS Res Hum Retroviruses; in press."},{"key":"10.1016\/j.jhep.2005.11.027_bib22","first-page":"1722","article-title":"Acute hepatitis in HIV-infected patients during ritonavir treatment","volume":"12","author":"Arribas","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/339867","article-title":"Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and HIV","volume":"34","author":"Cooper","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1592\/phco.20.13.1135.35024","article-title":"Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection","volume":"20","author":"Pai","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jhep.2005.11.027_bib25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.11.027_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2003-39949","article-title":"Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors","volume":"23","author":"Sulkowski","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib27","first-page":"36","article-title":"Hepatotoxicity of antiretroviral therapy","volume":"5","author":"Kontorinis","year":"2003","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jhep.2005.11.027_bib28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/339867","article-title":"Hepatitis associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus","volume":"334","author":"Cooper","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib29","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1097\/00002030-200411190-00008","article-title":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir","volume":"18","author":"Sulkowski","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib30","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1089\/0889222041524562","article-title":"Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection","volume":"20","author":"Gonz\u00e1lez-Requena","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jhep.2005.11.027_bib31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1468-1293.2004.00232.x","article-title":"Lopinavir\/ritonavir treatment in HIV-antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation","volume":"5","author":"Meraviglia","year":"2004","journal-title":"HIV Med"},{"issue":"Suppl. 2","key":"10.1016\/j.jhep.2005.11.027_bib32","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1086\/381444","article-title":"Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors","volume":"38","author":"Sulkowski","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00002030-200501280-00007","article-title":"Atazanavir plus ritonavir or saquinavir, and lopinavir\/ritonavir in patients experiencing multiple virological failures","volume":"19","author":"Johnson","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14787210.3.1.9","article-title":"Tipranavir: a novel second-generation non-peptidic protease inhibitor","volume":"3","author":"Kandula","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jhep.2005.11.027_bib35","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","article-title":"Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway","volume":"12","author":"Brinkman","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00002030-199303000-00012","article-title":"Hepatomegaly with severe steatosis in HIV-seropositive patients","volume":"7","author":"Frieman","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2796.1994.tb01088.x","article-title":"Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy","volume":"235","author":"Bissuel","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.jhep.2005.11.027_bib38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1258\/0956462001916498","article-title":"Clinical features and risk factors of lactic acidosis following long term antiretroviral therapy: 4 fatal cases","volume":"11","author":"ter Hofstede","year":"2000","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib39","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/317449","article-title":"Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Promethius Study Group","volume":"3","author":"Gisolf","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.jhep.2005.11.027_bib40","first-page":"12","article-title":"On behalf of the FTC-302 Study Investigators and the FTC-302 Independent Clinical Steering Committee. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor","volume":"14","author":"Sanne","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-infected patients receiving nevirapine-containing antiretroviral therapy","volume":"15","author":"Mart\u00ednez","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib42","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1086\/343046","article-title":"A cohort study of nevirapin tolerance in clinical practice: french aquitaine cohort, 1997\u20131999","volume":"35","author":"Bonnet","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib43","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00126334-200204010-00003","article-title":"Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors","volume":"29","author":"Palmon","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2005.11.027_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1043-6618(02)00146-9","article-title":"Hepatotoxicity following nevirapine containing regimens in HIV-1-infected individuals","volume":"46","author":"De Maat","year":"2002","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jhep.2005.11.027_bib45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.11.027_bib46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine","volume":"4","author":"Mart\u00edn-Carbonero","year":"2003","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jhep.2005.11.027_bib47","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN study","volume":"363","author":"Van leth","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.027_bib48","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection","volume":"40","author":"Aranz\u00e1bal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib49","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/jhep.2001.23505","article-title":"Drug-induced liver injury: mechanisms and test systems","volume":"33","author":"Bissell","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.11.027_bib50","first-page":"109","article-title":"Cytokine-mediated hepatic apoptosis","volume":"133","author":"Leist","year":"1998","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2005.11.027_bib51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/75360","article-title":"The use of single-nucleotide polymorphism maps in pharmacogenomics","volume":"18","author":"McCarthy","year":"2000","journal-title":"Nat Biotechnol"},{"issue":"Suppl. 1","key":"10.1016\/j.jhep.2005.11.027_bib52","first-page":"S21","article-title":"A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients","volume":"34","author":"Stern","year":"2003","journal-title":"J AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib53","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib54","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(00)03137-8","article-title":"Idiosyncratic drug reactions: the reactive metabolite syndromes","volume":"356","author":"Knowles","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.027_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib56","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/j.1572-0241.2001.03779.x","article-title":"Jaundice and hepatocellular damage associated with nevirapine therapy","volume":"96","author":"Prakash","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2005.11.027_bib57","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1001\/archinte.161.20.2501","article-title":"DRESS syndrome associated with nevirapine therapy","volume":"161","author":"Alonso","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2005.11.027_bib58","first-page":"222","article-title":"A near-fatal hypersensitivity reaction to abacavir: case report and literature review","volume":"11","author":"Shapiro","year":"2001","journal-title":"AIDS Reader"},{"key":"10.1016\/j.jhep.2005.11.027_bib59","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1086\/339751","article-title":"Abacavir hypersensitivity reaction","volume":"34","author":"Hewitt","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib60","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7326\/0003-4819-137-2-200207160-00025","article-title":"Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2005.11.027_bib61","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(96)91459-2","article-title":"Hypersensitivity syndrome associated with zalcitabine therapy","volume":"347","author":"Tancrede-Bohin","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.027_bib62","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.11.027_bib63","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1086\/323783","article-title":"Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with HIV infection: a report of 12 cases","volume":"33","author":"Coghlan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib64","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1097\/00002030-200109070-00012","article-title":"Direct analysis of mitochondrial toxicity of antiretroviral drugs","volume":"15","author":"Foli","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib65","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/00002030-200211080-00009","article-title":"In creased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors","volume":"16","author":"Walker","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib66","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.027_bib67","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00126334-200303010-00004","article-title":"Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome","volume":"32","author":"Puoti","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2005.11.027_bib68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/517808","article-title":"Impact of treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV","volume":"177","author":"Rutschmann","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib69","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/00002030-199817000-00010","article-title":"Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?","volume":"12","author":"John","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib70","first-page":"116","article-title":"Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy","volume":"12","author":"Vento","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib71","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1089\/08892220050075264","article-title":"Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders?","volume":"16","author":"Gavazzi","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jhep.2005.11.027_bib72","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00002030-200209270-00008","article-title":"Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects","volume":"16","author":"Chung","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib73","first-page":"1939","article-title":"Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy","volume":"12","author":"Mastroianni","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib74","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1086\/317535","article-title":"Reactivation of Hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy","volume":"32","author":"Manegold","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib75","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/344892","article-title":"Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus\u2013HCV-coinfected patients","volume":"186","author":"Stone","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib76","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00002030-200204120-00001","article-title":"Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV\u2013HCV International Panel","volume":"16","author":"Soriano","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.027_bib77","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/422142","article-title":"Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection","volume":"39","author":"French","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.027_bib78","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00002030-200403260-00007","article-title":"Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine","volume":"18","author":"Mac\u00edas","year":"2004","journal-title":"AIDS"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882780500752X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882780500752X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T01:53:47Z","timestamp":1554688427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882780500752X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":78,"alternative-id":["S016882780500752X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2005.11.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}